PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that Marcas de Renombre (MDR), the company's exclusive distributor in Mexico has surpassed their first year minimum sales goal. In addition, the company is pleased to confirm that media advertising in Mexico is concurrently increasing.
"I am very excited to announce that our distributor in Mexico has exceeded the contractual obligation of $480,000 of purchased product this quickly," said Luis Lopez, CEO of PharmaRoth. "The Agreement called for this minimum to be bought in the initial year in order to maintain exclusive status. The sales are media driven and even though the approval for the advertising from the Ministry took much longer than anticipated, sales has been accelerated now that the budget from MDR towards Sucanon® has been increased to meet the demand."
Lopez continues: "As previously announced, our proprietary Type II Diabetes drug is being sold thru retail and wholesale channels backed by aggressive media advertising all throughout Mexico. The product has never enjoyed this level of availability in any market before so it is hugely exciting to be able to provide a safe and effective drug for those afflicted with such a serious disease."
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth
PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.
For Investor Relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
mike@parvise.com
SOURCE: PharmaRoth Labs, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
ROTH_4-16-14_MEL_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment